Introduction
The nuclear factor-kB (NF-kB) family of eucaryotic transcription factors plays multiple roles in the inducible expression of genes involved in diverse biological processes, including development, immune/inflammatory responses, cell growth/death, stress responses, and carcinogenesis. NF-kB is activated in response to physical and chemical stress, bacterial lipopolysaccharide, double-stranded RNA, T-and B-cell mitogens, and proinflammatory cytokines (Rothwarf and Karin, 1999; Beyaert et al., 2000; Karin and Lin, 2002; Li and Verma, 2002) , among others. In resting cells, the majority of NF-kB is sequestered in the cytoplasm in complexes with I-kB inhibitory proteins. Phosphorylation of I-kBs leads to protein-ubiquitination that is followed by proteosome-mediated degradation. Once freed from I-kB, NF-kB translocates into the nucleus and activates the transcription of cognate genes (Chen et al., 1996; Whiteside and Israel, 1997) . Recent findings show that the I-kB kinase (IKK) complex that is composed of at least three subunits, catalytic IKKa and IKKb, and regulatory NF-kB essential modulator (NEMO), critically phosphorylates I-kB proteins (Scheidereit, 1998; Karin, 1999; Courtois et al., 2001) .
IKKa and IKKb are highly homologous proteins with an N-terminal protein kinase domain as well as leucine zipper and helix-loop-helix motifs (DiDonato et al., 1997; Mercurio et al., 1997; Zandi et al., 1997) . Despite their structural similarities, IKKa and IKKb have distinct functions. IKKb is approximately 20-fold more active than IKKa in phosphorylating I-kB (Mercurio et al., 1997) ; and IKKb, but not IKKa, knockout mouse fibroblasts have impaired NF-kB activation in response to proinflammatory cytokines (Hu et al., 1999; Li et al., 1999a, b, d; Takeda et al., 1999; Tanaka et al., 1999) . The NEMO (IKKg) subunit of the IKK complex is a coiled-coil protein devoid of kinase activity (Rothwarf et al., 1998; Yamaoka et al., 1998) . However, genetic experiments have shown that loss of NEMO function entirely eliminates NF-kB activation by all proinflammatory cytokines (Makris et al., 2000; Rudolph et al., 2000; Schmidt-Supprian et al., 2000) . Current thinking is that NEMO functions as a 'universal' scaffold protein adapting various upstream NF-kB-activating signals (Courtois et al., 1997) to a high molecular weight (HMW) intracellular IKKa/b complex (DiDonato et al., 1997; Mercurio et al., 1997; Zandi et al., 1997) . However, in its role as a 'universal' adaptor, how NEMO integrates the various activating signals, and whether all impinges on NEMO identically or divergently remain unclear. If divergent mechanisms are utilized, conceivably one could selectively attenuate some NF-kB stimuli without affecting others. Should one have enough information regarding separable NEMO functional domains, conceivably selective intracellular disruption could be effected using small-cellpermeable peptides (May et al., 2000) .
NF-kB plays parallel roles in immunity/inflammation, apoptosis, and cellular proliferation . In selective settings, interdiction against one NF-kB activity might be highly useful provided that the other NF-kB axes are preserved. For example, in treatment approaches for adult T-cell leukemia (ATL), an HTLV-I-engendered leukemia (Hinuma et al., 1981; Yoshida et al., 1982; Yoshida, 2001) , selective abrogation of Tax-NF-kB signaling without affecting other paths used for immunity or for protecting normal cells from TNFainduced killing would be very desirable. Such an interruption could be possible if NEMO structure/ function can be dissected in a manner that segregates Tax from proinflammatory cytokine activation. Here, we show molecularly discrete signaling through NEMO by Tax and TNFa. We provide evidence that activation by the former can be selectively abrogated without affecting the latter.
Results

NEMO-specific monoclonal antibodies differentially inhibit intracellular Tax versus TNFa signaling
Monoclonal antibodies (mAbs) directed to human extracellular receptors/proteins have achieved emerging therapeutic promise (Ranson and Sliwkowski, 2002; Ghosh et al., 2003) . With the advent of efficient proteintransfection technology, targeting and/or characterization of intracellular factors using mAbs seems increasingly feasible. To better understand the nuances of NEMO modulation, we generated four new anti-NEMO IgG1 mAbs, AB6-9, FG10-3, DA10-12, and EA2-6, by immunizing Balb/C mice with full-length human NEMO. Recognition specificities were characterized by probing nine immunoblotted GST-NEMO subfragments (Figure 1a Regions that are deductively recognized by the four mAbs are in color: AB6-9 is shown in green, DA10-12 and FG10-3 are shown in blue, and EA2-6 is shown in red Discrete signaling through NEMO/IKKc by TNFa and Tax H Iha et al 2, lanes 2 and 3). A third clone, AB6-9 (Figure 1b , panel 4, lanes 1 and 4), recognized a separate N-terminal epitope located in amino acids 1-61, while the fourth clone, EA2-6, recognized three NEMO subfragments, panel 3, . These results permitted the deduction of the minimal regions needed for recognition by each of the four mAbs (summarized in Figure 1c) .
We also checked the reactivity of our monoclonals to mammalian cell-endogenous NEMO. (Similar results were seen with all four monoclonals; representative EA2-6 data are presented in Figure 2 .) We first compared wild-type mouse embryo fibroblast (E6i) to the counterpart fibroblast from NEMOÀ/À knockout mouse (E8i). Cells, in parallel, were fixed, incubated with anti-NEMO monoclonal, and visualized by confocal microscopy using FITC-conjugated anti-mouse secondary antibody (Figure 2a ). When compared to nuclear staining using 4,6-diamidino-2-phenylindole (DAPI), NEMO presented as fine cytoplasmic granules in NEMO þ / þ , but not NEMOÀ/À, fibroblasts ( Figure 2a) . Next, we immunoblotted human epithelial HeLa) or primary foreskin (Hs27) cells with EA2-6 and identified a B50 kDa doublet ( Figure 2b ) that resolved into several discrete spots by two-dimensional isoelectric focusing ( Figure 2c ). These latter results are consistent with the specific recognition by our mAb of multiply phosphorylated forms of human NEMO (Prajapati and Gaynor, 2002; Tarassishin and Horwitz, 2001) . Our aim for the mAbs was to see if they could be used to target NEMO intracellularly , and whether such targeting could help us segregate interactions used by Tax from that used by TNFa for activating NF-kB.
Toward this goal, we explored a cationic lipid-based protein-transfection system (Pro-Ject, Pierce) for introducing mAbs into HeLa cells (Figure 3 ). The conditions for X50% 'pro-jection' into HeLa cells were first established using an FITC-tagged control mouse mAb (Figure 3a) . We also found that plasmid DNA could be cointroduced into cells with similarly high efficiency when mixed with mAb and cationic lipid (data not shown).
We next asked whether mAbs directed against three different NEMO epitopes (1-61 (AB6-9), 61-137 , and 262-319 (EA2-6)) would segregate intracellular activation of NF-kB by Tax versus TNFa. We separately mixed each mAb with a Tax expression plasmid and an NF-kB-luciferase reporter (NF-kB-luc), and introduced them all together into cells. Luciferase activities were assayed 16 h later. In Tax cells, all three monoclonals (AB6-9, EA2-6, and FG10-3; Figure 3b , lanes 2-4) consistently inhibited the activation of NF-kB by 50-70% (Figure 3b , lane 1). On the other hand, TNFa-treated cells offered a different picture. Here, while AB6-9 and FG10-3 ( Figure 3c , lanes 2, 4) inhibited NF-kB activity by 60-75%, EA2-6 (Figure 3c , lane 3) actually enhanced activity by approximately 25%. The magnitudes of these effects are comparable to the previously reported B3-fold inhibition achieved with cell-permeable peptides targeted to NEMO (May et al., 2000) .
To verify the specificity of our finding for Tax/NF-kB, we performed two additional controls. We 'pro-jected' our NEMO mAbs into cells with an AP-1-responsive reporter expressing significant basal luciferase activity. When luciferase activities were assayed 16 h later, we observed no perturbation of reporter expression with any of the monoclonals ( Figure 3d ). Next, we 'projected' Tax-specific EA2-6 mAb in parallel separately into an HTLV-I-transformed T-cell (MT4) or a control T-cell line (Jurkat). We reasoned that should the EA2-6 effect be Tax specific and should proliferation of MT4 be driven by Tax activation of NF-kB, then growth of MT4, but not Jurkat, might be affected. Indeed, based on quadruplicate MTT readouts, EA2-6 selectively reduced the proliferation of MT4 cells (Figure 3e ). Collectively, these results support the specificity of the observed Tax/TNFa/NF-kB findings (Figure 3b , c), ruling out trivial consequences of cellular toxicity ( Figure 3d ).
Different requirements for NEMO coimmunoprecipitation with IKKa/b and association with HMW intracellular IKK
The different antibody inhibition profiles suggested nonidentical interactions between Tax and TNFa with NEMO. We attempted to confirm this notion through a more conventional approach using NEMO mutants that might distinguish Tax from TNFa activation of NF-kB. Commencing with the coiled-coil (six putative coils, CC1 to CC6; Figure 4a ) full-length 419 amino-acid human NEMO protein, we generated 10 serial deletion mutants, each tagged at their N-terminus with a FLAG epitope ( Figure 4b ). All mutants were confirmed by immunoblotting (IB) with anti-FLAG to express comparably when transfected into human cells ( Figure 4c ).
As a first characterization step, we tested the respective capacity of the NEMO mutants to coimmunoprecipitate (co-IP) IKKa and IKKb. HA-tagged wild-type NEMO, HA-tagged IKKb or HA-tagged IKKa was transfected into 293T cells with an individual FLAG-tagged NEMO mutant ( Figure 5a ). Cell lysates were immunoprecipitated with anti-FLAG, and co-precipitated protein(s) was detected by IB with anti-HA. FLAG-NEMO 1-419, 1-370, 1-305, 1-245, 1-195 and 51-419 co-IPed HA-IKKa and HA-IKKb ( Figure 5a , top, middle) mapping a minimal IKKa/bbinding region to the first three NEMO coiled coils (CC1, CC2, CC3; amino acids 51-195, Figure 4a) . Interestingly, when we tested whether NEMO mutants oligomerize by checking whether FLAG-tagged NEMO would co-precipitate HA-tagged NEMO, we found that the FLAG 1-419, 1-370, 1-305, 1-245, 51-419, 91-419, 196-419, and 246-419 suggest that the N-terminus of NEMO recognizes IKKa and IKKb identically in co-IPs. We have no explanation as to why these findings differ slightly from the co-IPs of Tegethoff et al. (2003) , who reported a selective contribution by amino acids 1-65 of NEMO for binding IKKa, but not IKKb. Co-IPs do not address whether the observed association between two proteins is a component of a larger multiprotein framework. As the biological form of cytokine-activated NF-kB kinase is a HMW 600-900 kDa complex (Chen et al., 1996; Mercurio et al., 1997; Zandi et al., 1997; Rothwarf et al., 1998; Mercurio et al., 1999; Li et al., 2001) , the relevant protein-protein interaction would be one which specifies an association with HMW IKK. Previous co-IP studies (Ye et al., 2000; Xiao et al., 2000) We separately expressed FLAG-wild-type and five FLAG-NEMO mutants in HeLa cells. S100 lysates were prepared and chromatographed over a Superose 6 FPLC column (Figure 5b ), and fractions were collected and aligned with molecular size standards. All samples were immunoblotted with anti-IKKa, anti-IKKb, anti-NEMO, or anti-FLAG as indicated. Within the general resolution of this technique, we observed that the majority of two NEMO mutants, 1-95 and 301-419, chromatographed as low molecular weight (o232 kDa) entities that we interpret to be most consistent with protein monomers. By contrast, three other NEMO mutants 1-195, 1-245, and 246-419 distributed towards higher molecular weight fractions, a behavior more consistent with protein oligomers (Figure 5b , . When cellendogenous IKKa and IKKb were analysed, these Figure 4c . A total of 100 mg of cell lysates were subjected to IP with 2 mg of mouse monoclonal anti-FLAG antibody (anti-FLAG), followed by IB with rabbit polyclonal anti-HA antibody (anti-HA) (upper panel). The transfection efficiency was verified by IB with anti-HA (lower panel). In each case, the expression of the FLAGtagged NEMO was verified as shown in Figure 4c Figure 5b) ; similarly, FLAG-full-length NEMO also distributed into these fractions (Figure 5b , FLAG-NEMO 1-419). On the other hand, when we checked for the presence of NEMO mutants in the 4669 kDa region, we found approximately 15% of FLAG-NEMO 1-245 fractionated there, while less than 1% of mutants 1-95, 1-195, 246-419, or 301-419 was detected in the HMW fractions (Figure 5b, FLAG-NEMO 1-95,  1-245, 246-419, 301-419) . Hence, in distinction with co-IP results that showed that NEMO 1-245 and fulllength 1-419 protein precipitated IKKa/b indistinguishably (Figure 5a ), the chromatographic evidence indicated that NEMO 1-245 mutant, in the context of an HMW complex, associated less efficiently than full-length NEMO with cellular holo-IKK (Figure 5b) . Altogether, the chromatographical results suggest that amino acids C-terminal to position 95 of NEMO participates in oligomerization and that oligomerization, while seemingly unnecessary for co-IP with IKKa/ b, appears to be critical for NEMO to participate in intracellular HMW IKK complex formation.
Different NEMO domains participate in cytokineand tax-induced NF-kB activation
We next checked whether our NEMO mutants could distinguish between Tax versus cytokine activation of NF-kB. As a first step, we employed NEMO knockout mouse embryonic fibroblasts (E8i cells, Schmidt- Supprian et al., 2000) to check for functional complementation. NEMO is essential for the activation of NF-kB by TNFa, IL-1b, or Tax (Chu et al., 1999: Harhaj and Sun, 1999; Jin et al., 1999; Makris et al., 2000; Rudolph et al., 2000; Schmidt-Supprian et al., 2000) . As expected, in E8i cells, NF-kB could not be activated by TNFa, IL-1b, or Tax ( Figure 6 ; compare control lanes to TNFa, IL-1b, and Tax lanes). NF-kB activation by all three stimuli was uniformly rescued when full-length 1-419 NEMO was transfected into E8i cells (Figure 6 , NEMO 1-419 lanes). When different mutants were tested, only three exhibited activity. Mutant 51-419 was reproducibly more active than wild-type NEMO, while mutant 1-370 was fully active for Tax and IL-1b, and less active for TNFa. A third mutant, 1-245, was completely inactive for TNFa and IL-1b, but was partially active for Tax (Figure 6 ). These complementation results support the antibody inhibition findings that proinflammatory cytokines and Tax signal nonidentically through NEMO.
To distinguish differences between TNFa and Tax more clearly, we wondered whether some of the loss-offunction NEMO mutants would exhibit differential dominant-negative phenotypes. We explored seven E8i noncomplementing mutants, NEMO 1-95, 1-195, 1-305, 91-419, 196-419, 246-419 , and 301-419, in NEMO þ / þ E6i cells. Interestingly, when these mutants were checked for dominant-negative activity Figure 6 NEMO domains required for functional complementation of cytokine-or Tax-induced NF-kB activation. Mouse NEMO knockout E8i cells were transfected with 1 mg of total DNA containing a mixture of 100 ng of NF-kB-luc (Stratagene) with 100 ng of RSV-b-galactosidase, 10 ng of the indicated NEMO expression vectors, with or without 250 ng of the Tax expression vector and with the appropriately balanced amounts of carrier DNA. After 16 h of transfection, TNFa (2 ng/ml, a) and IL-1b (1 ng/ml, b) were added and incubated for 8 h. Cells were harvested for luciferase assay 24 h after transfection. Fold activation was based on the division of normalized luciferase values after activation by the normalized basal luciferase values (Figure 7b) . Thus, the different dominant-negative patterns further confirm (Figures 3 and 6 ) that TNFa and Tax work through separate NEMO domains. We were puzzled that most of our mutants failed to inhibit TNFa signaling. All mutants expressed robustly in cells when assayed by IB (Figure 4 and data not shown), suggesting that their lack of activity against TNFa cannot be explained by deficient intracellular synthesis. However, the mutants could possibly be misfolded or misdistributed intracellularly. To investigate this possibility, we constructed 10 green fluorescent forms of NEMO and checked their respective presentations in living cells (Figure 8 ). When expressed in mouse embryo fibroblasts, wild-type GFP-NEMO (Figure 8, 1-419 ) was nuclearly excluded and appeared as multiply discrete rounded cytoplasmic speckles. When N-terminal sequences were deleted progressively, the 51-419 and 91-419 proteins maintained the round cytoplasmic speckles (Figure 8 ; 51-419, 91-419); however, the 196-419, 246-419 mutants (Figure 8; lost their speckled organization, albeit their fluorescence remained cytoplasmic. When GFP-fused C-terminally deleted NEMO proteins were viewed, three, 1-195, 1-245, and 1-370, showed finely granulated cytoplasmic fluorescence. GFP-1-95, probably because of its small size, was distributed into both the nucleus and cytoplasm, while GFP-1-305, which is essentially identical to the previously described IKKgDC molecule (Rothwarf et al., 1998) consistently coalesced into large cytoplasmic aggregates (Figure 8, 1-305 ). To the extent that cytoplasmic speckling represents the correct folding/configuration of wild-type NEMO in a GFP-live-cell context, our results suggest that most mutants show some misfolding. That only one (i.e. 1-305) mutant is dominant negative for TNFa while four others could suppress Tax activity is compatible with different folding/structural requirements for NEMO to interact with the former versus the latter. These results further highlight the differences between Tax and TNFa in their respective activation of NF-kB through NEMO.
Discussion
NF-kB activity contributes to multiple biological processes including cell growth, cellular transformation and cell death (Beyaert et al., 2000; Karin and Lin, 2002; Li and Verma, 2002) . The HMW holo-IKK complex has been shown to be the critical biologically relevant kinase for NF-kB activation. Current thinking suggests that most, if not all, IKK-activating signals transits through the IKK-adaptor subunit NEMO. In this regard, both transformation of cells by HTLV-I oncoprotein, Tax (Nerenberg et al., 1987; Grassmann et al., 1989; Tanaka et al., 1990) , and cellular activation by proinflammatory cytokine, TNFa, have been shown to require NEMO. Genetic data from knockout mice (Makris et al., 2000; Rudolph et al., 2000; Schmidt-Supprian et al., 2000) have firmly established the physiological importance of NEMO for NF-kB activation by various signals. However, how NEMO is contacted by and responds to the variously converging signals remains incompletely elucidated. Here, using TNFa and Tax as two types of NEMO-activating stimuli, we show that the oncogenic and proinflammatory signals impinge upon different and separable domains of NEMO/IKKg.
Tax is unambiguously the cellular transforming factor for HTLV-I (Yoshida, 2001; Marriott et al., 2002) . The activation of NF-kB by Tax has been proposed as a causal viral mechanism for ATL (Ballard et al., 1988; Kitajima et al., 1992; Mori et al., 1994; Robek and Ratner, 1999; Tsukahara et al., 1999) . Accordingly, although it has yet to be contemplated, ATL therapy, in principle, would benefit from interruption of NF-kB activation. However, global inhibitory approaches using nonsteroidal anti-inflammatory drugs and/or immunosuppressive agents ) may be counterproductive, since such routes could abrogate NF-kB's oncogenic potential at the expense of blocking other NF-kB activities needed for normal cellular metabolism. As NEMO is a nexus at which many diverse signals converge, should one capably delineate discrete domains that subserve different types of signaling, then stimulus-specific interruption of NFkB-activation through targeting of NEMO might be practically feasible (Li et al., 1999c; Zhang et al., 2000; Orlowski and Baldwin, 2002) .
By introducing three independent mAbs into cells, we provide the first evidence that oncogenic and proinflammatory signaling through NEMO can be independently interrupted (Figure 3 ). Our approach builds upon the confluence of three emerging technologies: (i) the increasing efficacious use of mAbs in treating human pathologies (Ranson and Sliwkowski, 2002; Ghosh et al., 2003) , (ii) the finding that single-chain intracellular antibodies can effectively inhibit the function of cellular factors (Bai et al., 2003) , and (iii) the advent of commercially available high-efficiency protein-transfection reagents. Our intracellular antibody data provided two salient insights. First, the results confirmed in living cells the importance of the N-terminus of NEMO for contact with IKKa/b (May et al., 2000; Poyet et al., 2000; Ye et al., 2000) and the common role that this interaction serves for Tax and TNFa activation of NFkB. Second, the findings indicate that the central region of NEMO (i.e. amino acids 262-319) functions differently for Tax versus TNFa. Hence, the EA2-6 mAb inhibited Tax activation, while it enhanced TNFa activation ( Figure 3 ). Other explanations not excluded, one interpretation is that the EA2-6 may have a blocking as well as a stabilizing function for NEMO. This antibody may sterically obstruct the interaction between Tax and NEMO amino acids 304-339 (Xiao et al., 2000) , thereby perturbing activation. On the other hand, EA2-6 through its overlapping interaction with amino acids 242-388 or 246-365 could possibly stabilize NEMO trimerization/tetramerization (Agou et al., 2002; Tegethoff et al., 2003) leading to enhanced TNFa responsiveness. Additional physical studies are pending in order to confirm these reasonings.
To further investigate the notion that TNFa and Tax signal differently, we also created 10 function-retaining or loss-of-function NEMO mutants (Figures 4, 6 and 7) . The 10 mutants yielded instructive findings regarding structured domains required for NEMO function. Initially, in co-IPs, we found, as expected from previous reports (May et al., 2000; Poyet et al., 2000; Ye et al., 2000) , that amino acids 1-195 and 196-245 described minimal NEMO domains needed, respectively, for coprecipitating IKKa/b and for self-co-precipitation (Figure 5a ). Intriguingly, when we further asked as to what portion of NEMO was needed for association with HMW (4669 kDa) cellular holo-IKK, a more complicated scenario emerged. In this context, full-length NEMO intercalated efficiently, while NEMO 1-245 intercalated partially into HMW IKK (Figure 5b ). On the other hand, neither NEMO 1-195, 246-419 nor 301-419 could be detected with HMW IKK (Figure 5b) . Hence, different from that required for NEMO to co-IP IKKa/b, both the 1-195 (contact) and the sequences Cterminal to 196 (oligomerization region) are needed for a biologically relevant association of NEMO with intracellular HMW IKK. This conclusion supports recent proposals that trimerization/tetramerization of NEMO is important for function (Poyet et al., 2000; Agou et al., 2002; Huang et al., 2002; Tegethoff et al., 2003) and suggests that NEMO oligomerization is a functional prerequisite for its association with HMW IKK.
Two additionally unexpected findings emerged from our complementation and dominant-negative experi- -1-419, 51-419, 91-419, 196-419, 246-419, 1-95, 1-195, 1-245, 1-305, and 1-370 . Cells were visualized 24 h later Discrete signaling through NEMO/IKKc by TNFa and Tax H Iha et al ments (Figures 6, 7) . First was the observation that NEMO 1-245 supported Tax activation ( Figure 6 ). That NEMO 1-245 could complement Tax in E8i cells was surprising, since previously it was argued that mouse NEMO sequences spanning 304-339 were required to bind Tax in co-IP assays (Xiao et al., 2000) . Recently, when this issue was re-examined, others (Huang et al., 2002) and we (Iha, data not shown) found that Tax actually bound the 201-250 region of human NEMO directly. Thus, while sequence 304-339 may contribute an important conformational influence on NEMO function (Figure 3) , it is the NEMO sequence upstream of position 245 that represents the direct Tax-binding target. In the context of the above finding, a second curios finding was that mutant 1-305 failed to support Tax function ( Figure 6 ) and, in fact, dominantly inhibited both TNFa and Tax activation of NF-kB ( Figure 7 ). Human NEMO mutant 1-305 is essentially identical to the prevalently used dominant-negative mouse IKKgDC previously described elsewhere (Rothwarf et al., 1998) . It was perplexing that human NEMO 1-245 provided partial complementation, while human NEMO 1-305 was dominant negative. However, when we visualized GFP-NEMO 1-305 in living cells, it, unlike any other mutant that we surveyed, formed unusual cytoplasmic aggregates (Figure 8 ). This particular presentation could explain why NEMO 1-305 dominantly inhibited TNFa activation of NF-kB, while other loss-of-function mutants in our assays showed no comparable inhibitory activity (Figure 7 ). Of interest, we also noted that unfixed GFP-full-length NEMO in living cells showed prominent punctate cytoplasmic speckles (Figure 8 , 1-419) reminiscent of that previously described for FKBP12-enforced oligomerization/trimerization of a chimeric GFP-IKKg-truncated protein ( Figure 6 in Poyet et al., 2000) . This observation suggests that some amount of native NEMO (as well as mutant proteins that contain sequences from 91 to 419) may constitutively exist as oligomers/trimers without requiring stimulus induction (Figure 8 ). By contrast, partially active mutants such as 1-245 may be constitutively oligomerization inefficient, but can be driven to oligomerize by the appropriate cofactors and stimuli (Huang et al., 2002) . Finally, the key message of our study is the discrete segregation of NEMO domains used by Tax and TNFa. Future studies remain necessary to clarify the NEMOdownstream mechanistic differences between Tax and TNFa for NF-kB activation. Nevertheless, as an initial step towards better therapeutic applications, we are encouraged that intracellular antibody targeting the NEMO 262-319 region can regress the proliferative growth of Tax-transformed T-leukemic cells without toxicity for control T cells (Figure 3) . Conceivably, cellpermeable peptides (May et al., 2000) targeting this portion of human NEMO might provide novel-specific adjuncts to conventional ATL therapy. Alternatively, an EA2-6 Fab fragment fused to a protein-transduction domain could possibly be therapeutic for ATL. Future investigations following these lines of thought appear to be warranted.
Materials and methods
Prediction of coiled-coil structure on human NEMO
The coiled-coil domains of human NEMO were predicted by MacStripe 2.0 version with the window size of 21 (Lupas et al., 1991) .
Cells and cell-culture conditions
Immortalized mouse embryonic cell, E6i and its NEMO knockout counterpart E8i, were a kind gift from Dr Marc Schmidt-Supprian; (Schmidt-Supprian et al., 2000) , Hs27 (primary human foreskin fibroblast), 293T, HeLa, MT4, and Jurkat cell lines were obtained from ATCC. All adherent cells were cultured in complete DMEM/high glucose with 10% fetal bovine serum. Suspension cells were cultured in complete RPMI-1640 supplemented with 10% FBS. The cell proliferation assay with a modified MTT dye reduction assay was as previously described .
Plasmids
IKKa, IKKb, NEMO, and Tax were amplified from vectors previously described (Mercurio et al., 1997; Jin et al., 1999; Ng et al., 2001 ) and cloned into pcDNA3 (Invitrogen). GFP-NEMO expression vectors were cloned into pEGFP-C3 (Clontech). pGEX-IKKg was previously described (Jin et al., 1999) . Other GST-NEMO fusion fragments were cloned into pGEX-4T1 (Amersham Pharmacia Biotech). All vectors were verified by sequencing.
Co-IP and IB
A total of 1 Â 10 6 cells of 293T were transfected with 1 mg of each plasmid by TransIT LT1 (Mirus). After 24 h, cells were lysed (0.5% Nonidet P-40, 50 mM HEPES (pH 7.3), 150 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM sodium orthovanadate (Na 3 VO 4 ), 1 mM sodium fluoride (NaF), 10% glycerol and protease inhibitor mix (Roche)). In all, 100 mg of lysates were precleared with 30 ml of protein G/A agarose (Oncogene Research Products) for 2 h and incubated with 2 mg of mouse monoclonal anti-FLAG antibody (M2, Sigma) and 30 ml of protein G/A agarose for at least 3 h at 41C. Antibody-agarose complexes were washed 3 Â with lysis buffer, resolved by 10 or 12% SDS-poly acrylamide gel electrophoresis (SDS-PAGE) and transferred onto a PVDF membrane (Millipore) using conditions previously described (Kibler and Jeang, 2001) . HA-tagged IKKs were detected by rabbit polyclonal anti-HA antibody (Sigma); Tax, by anti-Tax mAbv from NIH AIDS Research Reference Reagent program.
FPLC protein fractionation and IB
Cytoplasmic extracts were prepared with slight modifications. A total of 1.6 Â 10 7 of HeLa cells were transfected with 10 mg of pcDNA3 vectors expressing FLAG-NEMO or truncation mutants using Monster HeLa (Mirus) and harvested 24 h later. Cells washed 2 Â with cold PBS were pelleted at 1500 r.p.m. for 5 min. Pellets were resuspended into buffer A (10 mM HEPES (pH 7.9), 1 mM EDTA, 10 mM KCl, 1 mM dithiothreitol (DTT)) supplemented with phosphatase inhibitors (50 mM NaF, 50 mM glycerol phosphate, 1 mM Na 3 VO 4 ) and proteinase inhibitors. After incubation on ice for 15 min, cells were disrupted with 20 strokes through a 25-gauge needle and centrifuged at 16 000 g for 15 min. The supernatants were mixed with 0.11 volume of Discrete signaling through NEMO/IKKc by TNFa and Tax H Iha et al buffer B (0.3 M HEPES (pH 7.9), 30 mM MgCl 2 , 1.4 M KCl) and centrifuged at 100 000 g for 60 min. In total, 2 mg of supernatant (S100) were subjected to Superose 6 HR 10/30 (Amersham Pharmacia Biotech) chromatography in buffer D (20 mM HEPES (pH 7.9), 0.1 M KCl, 0.5 mM DTT, 0.5 mM PMSF, 20% glycerol, and 0.2 mM EGTA), and 0.9-ml fractions were collected. Protein markers (Amersham Pharmacia Biotech) were thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), aldolase (158 kDa), and bovine serum albumin (66 kDa). Proteins (30 mg) from fractions 12-24 in each chromatographic run were precipitated with TCA, subjected to 10 or 12% SDS-PAGE and detected with monoclonal anti-FLAG M2, monoclonal anti-IKKa and anti-IKKb antibodies (Oncogene Research Products), or monoclonal anti-NEMO.
Luciferase assay
The transfection of cells was as previously described (Iha et al., 2000) . Briefly, 1 Â 10 5 cells of E6i and E8i were transfected with 1 mg of plasmid DNA mixture containing reporter plasmids, 100 ng of NF-kB-luc (Stratagene) and 100 ng of RSV-bgalactosidase, by TransIT LT1. The total DNA was normalized by the addition of pcDNA3. After 16 h, where indicated, mouse TNFa (Calbiochem) or IL-1b (Sigma) at concentrations of 2 or 1 ng/ml, respectively, were added for 8 h. Luciferase was measured 24 h after transfection in an Opticom II luminometer (MGM Instruments). Cell extracts used for luciferase assay were quantitated for b-galactosidase activity using GalactoStar (Tropix), and normalized based on b-galactosidase readings.
Confocal microscopy
E6i cells were cultured on 25 mm coverslips (Thomas Scientific) and transfected with 500 ng of GFP-NEMO plasmid. Cells were fixed with 3.7% formaldehyde and stained with DAPI ( Molecular Probes). Coverslips were mounted onto glass slides with a ProLong Antifade Kit (Molecular Probes) and examined with a Leica DM IRBE laser-scanning microscope .
mAb production and transfection into cells
Balb/C mice were injected with purified GST-IKKg. Spleen cells of positive mice were cultured with NSI myeloma cells (ATCC), individual hybridomas were isolated, clone supernatants were screened by ELISA, Western blotting, and immunoprecipitation. Ascites were produced in mice (Spring Valley, Woodbine, MD, USA). The IgG isotype was determined with Mouse Typer Sub-Isotyping Kit (Bio-Rad) according to the manufacturer's instructions; all four clones are IgG 1 . For the transfection of antibody into cells the Project Protein Transfection Reagent Kit (Pierce) was used according to the manufacturer's protocol.
Isoelectric focusing
Separation was performed in the PROTEAN IEF Cell system (BioRad) according to the manufacturer's instructions. Proteins bound to immobilized pH gradient gel strips were then electrophoresed in 10% precast polyacrylamide gels (BioRad).
